A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope

Glypican 2 (GPC2) is a MYCN-regulated, differentially expressed cell-surface oncoprotein and target for immune-based therapies in neuroblastoma. Here, we build on GPC2’s immunotherapeutic attributes by finding that it is also a highly expressed, MYCN-driven oncoprotein on small-cell lung cancers (SC...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cell Rep Med
Main Authors: Raman, Swetha, Buongervino, Samantha N., Lane, Maria V., Zhelev, Doncho V., Zhu, Zhongyu, Cui, Hong, Martinez, Benjamin, Martinez, Daniel, Wang, Yanping, Upton, Kristen, Patel, Khushbu, Rathi, Komal S., Navia, Carmen T., Harmon, Daniel B., Li, Yimei, Pawel, Bruce, Dimitrov, Dimiter S., Maris, John M., Julien, Jean-Philippe, Bosse, Kristopher R.
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2021
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8324494/
https://ncbi.nlm.nih.gov/pubmed/34337560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.xcrm.2021.100344
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares